Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI

D.R. Johnson, F.E. Diehn, C. Giannini, R.B. Jenkins, S.M. Jenkins, I.F. Parney and T.J. Kaufmann

AJNR Am J Neuroradiol 2017, 38 (4) 678-684
doi: https://doi.org/10.3174/ajnr.A5070
http://www.ajnr.org/content/38/4/678
Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI

D.R. Johnson, F.E. Diehn, C. Giannini, R.B. Jenkins, S.M. Jenkins, I.F. Parney, and T.J. Kaufmann

ABSTRACT

BACKGROUND AND PURPOSE: In 2016, the World Health Organization revised the brain tumor classification, making IDH mutation and 1p/19q codeletion the defining features of oligodendroglioma. To determine whether imaging characteristics previously associated with oligodendroglial tumors are still applicable, we evaluated the MR imaging features of genetically defined oligodendrogliomas.

MATERIALS AND METHODS: One hundred forty-eight adult patients with untreated World Health Organization grade II and III infiltrating gliomas with histologic oligodendroglial morphology, known 1p/19q status, and at least 1 preoperative MR imaging were retrospectively identified. The association of 1p/19q codeletion with tumor imaging characteristics and ADC values was evaluated.

RESULTS: Ninety of 148 (61%) patients had 1p/19q codeleted tumors, corresponding to genetically defined oligodendroglioma, and 58/148 (39%) did not show 1p/19q codeletion, corresponding to astrocytic tumors. Eighty-three of 90 (92%) genetically defined oligodendrogliomas had noncircumscribed borders, compared with 26/58 (45%) non-1p/19q codeleted tumors with at least partial histologic oligodendroglial morphology (P < .0001). Eighty-nine of 90 (99%) oligodendrogliomas were heterogeneous on T1- and/or T2-weighted imaging. In patients with available ADC values, a lower mean ADC value predicted 1p/19q codeletion (P = .0005).

CONCLUSIONS: Imaging characteristics of World Health Organization 2016 genetically defined oligodendrogliomas differ from the previously considered characteristics of morphologically defined oligodendrogliomas. We found that genetically defined oligodendrogliomas were commonly poorly circumscribed and were almost always heterogeneous in signal intensity.

ABBREVIATIONS: IDH = isocitrate dehydrogenase; WHO = World Health Organization
sharply delineated margins, calcification, and internal cysts. These features must be re-evaluated following the WHO 2016 brain tumor update because those tumors previously classified as oligodendrogliomas or oligoastrocytomas but lacking 1p/19q codeletion are now considered astrocytomas, and those tumors previously called oligoastrocytomas containing the IDH mutation and 1p/19q codeletion are now classified as oligodendrogliomas. Thus, it is not clear whether the features previously considered typical of oligodendroglia are able to characterize genetically defined WHO 2016 oligodendrogliomas and distinguish them from astrocytomas.

We evaluated a large series of patients with morphologically defined oligodendrogial tumors (oligodendroglioma and oligoastrocytoma by WHO 2007 criteria) to determine whether MR imaging features could identify those patients with true genetically defined WHO 2016 oligodendrogliomas and distinguish them from astrocytomas.

**MATERIALS AND METHODS**

**Patient Identification and Study Design**

Institutional review board approval with waived consent was obtained for this Health Insurance Portability and Accountability Act–compliant retrospective research study. Our institutional neuropathology data base was used to identify patients 18 years of age and older with WHO grade II or III infiltrating gliomas originally diagnosed as oligodendrogliomas and oligoastrocytomas whose tumors had undergone 1p/19q fluorescent in situ hybridization testing to assess codeletion. This testing was performed on tumors that contained oligodendrogliarial elements at microscopy based on the 2007 WHO brain tumor classification system. Patients were excluded if the tumor was classified as an astrocytoma or a morphologic tumor subtype could not be assigned; if they did not have at least 1 MR imaging study containing both T1- and T2-weighted images obtained before surgical intervention; or if they had received any chemotherapy or radiation therapy. Two board-certified neuroradiologists blinded to patient 1p/19q status and histopathology evaluated preoperative MR images at a digital workstation (Advantage Workstation 4.3; GE Healthcare, Milwaukee, Wisconsin) and performed image analysis in consensus. The MR imaging examinations were performed at our institution and at outside institutions that had referred patients to us. Pulse sequences generally included pre- and postgadolinium T1- and T2-weighted imaging and T2-weighted FLAIR imaging. Other sequences, DWI, gradient-echo T2*-weighted, and DSC perfusion imaging, were not consistently available.

Tumor location was assessed by the primary lobe of involvement and by whether the tumor burden was unilateral or bilateral (by crossing the midline or by multifocal disease). The following classifications were noted to reflect the predominant nature of each tumor: tumor margins completely circumscribed, partially circumscribed, or noncircumscribed (Fig 1); borders predominantly sharply interfaced with normal brain or indistinct (T1- and T2-weighted sequences) (Fig 2); contour predominantly smooth or irregular (Fig 2); and internal homogeneity versus nonhomogeneity (T1- and T2-weighted sequences). Circumscription of tumor margins was judged as a summary marker from all pulse sequences and was considered complete if >75% of the tumor circumference was geographically marginated, as if one could trace a pencil line around the tumor. Partial circumscription was present if 50%–75% of the tumor circumference was circumscribed, and lack of circumscription was present if <50% of the tumor circumference was circumscribed. The judgment of sharp-versus-indistinct tumor borders was considered potentially related to circumscription and overlapping with it but more specifically looking at whether tumor interfaces with brain were sharp or blurred individually on both T1- and T2-weighted pulse sequences. Sharp-versus-indistinct border was chosen to reflect the strong predominance of the character of a given tumor.

The judgment of tumor contour as smooth or irregular was also considered potentially related to circumscription and tumor border sharpness but was specifically focused on whether tumor margins were convex outward as a predominant characteristic of a given tumor on T2-weighted images versus a mix of tumor margins convex outward and concave inward. Necrosis or cystic

**FIG1.** Examples of circumscribed (A and D), partially circumscribed (B and E), and noncircumscribed (C and F) tumor borders on axial T1-weighted (upper row) and T2-weighted (lower row) MR images.
change and the presence or absence of contrast enhancement were also determined. Paramagnetic susceptibility effect (or loss of signal, which might indicate hemorrhage or calcification) was evaluated with T2*-weighted imaging when available; otherwise, we assessed focal T1 shortening and/or focal signal loss on T2-weighted images. When available, mean and median overall ADC was measured for each tumor from 2D ROIs. Given frequent glioma heterogeneity, we also sampled the highest and lowest ADC areas within each tumor by placing four 15- to 22-mm² ROIs in areas of visually low and high tumoral ADC, and the means of these low and high ADC ROIs were calculated, followed by measures of central tendency of those mean values across patients.

Pathologic Correlation
Tumor histopathologic diagnoses were obtained from pathology reports in the electronic medical record. Diagnoses were determined by board-certified neuropathologists by using the WHO 2007 update criteria. The 1p/19q codeletion status, as determined by fluorescence in situ hybridization, was obtained from clinical records. IDH1- and IDH2- mutation analysis was available in a subset of cases; sequencing methods have been previously described. For this evaluation, the term “genetically defined oligodendroglioma” is used for pathologically proved WHO grade II and III infiltrating gliomas, which contain 1p/19q codeletion by fluorescence in situ hybridization; and the term “astrocytoma” is used in the absence of 1p/19q codeletion. From a technical standpoint, knowledge of IDH mutation is necessary for complete classification, and this was only available in a subset of patients. However, IDH mutation is always present in patients with 1p/19q codeleted oligodendroglioma and is likely present in at least 80% of the noncodeleted tumors in this study, because the association between oligodendrogial morphology at microscopy and IDH mutation is well-established.

Statistical Analyses
The associations of 1p/19q codeletion status with the recorded imaging features, tumor type, and tumor grade were assessed. Data were compared between groups with χ² tests or Fisher exact tests (when appropriate) for nominal variables and with the Kruskal-Wallis test for continuous or ordinal variables. Multivariable logistic regression models were used to assess the association of 1p/19q codeletion (genetic oligodendroglioma classification) with imaging characteristics, and results were summarized with odds ratios, 95% confidence intervals, and C statistics. All analyses were performed by using SAS, Version 9 (SAS Institute, Cary, North Carolina).

RESULTS
Study Population
One hundred eighty-five patients with previously untreated WHO grade II or III infiltrating gliomas who underwent tumor 1p/19q codeletion testing at the time of the first operation were identified. We excluded patients with the following: morphologically pure astrocytic tumors (n = 26), age younger than 18 years at the time of diagnosis (n = 5), either T1- or T2-weighted MR imaging sequences unavailable (n = 2), research authorization declined (n = 2), tumor that could not be assigned a morphologic subtype (n = 1), and prior craniotomy at another institution (n = 1). One hundred forty-eight patients with infiltrating gliomas with histologic oligodendrogial morphology met the criteria for inclusion. Of these, 90 of 148 (61%) demonstrated 1p/19q codeletion and 58 of 148 (39%) did not. Patient demographic characteristics are shown in Table 1. MR images were predominantly 2D rather than 3D volumetric, and most scans were performed at 1.5T.

Tumor Histology and IDH-Mutation Status
Histologic tumor characteristics and IDH-mutation statuses are shown in Table 2. Thirty-six of 42 (86%) tumors previously characterized as oligodendrogliomas were 1p/19q codeleted, and 6 of 42 (14%) were not. Of the 106 tumors previously classified as oligoastrocytomas by the 2007 criteria, 54 (51%) were 1p/19q codeleted and 52 were not, corresponding to astrocytoma, IDH-
mutations of either IDH1 or IDH2, making them oligodendrogliomas by the WHO 2016 classification system. Among the tumors without 1p/19q codeletion, of those 21 in which IDH status was known, 19 (90%) demonstrated mutation.

**Tumor Location**

The proportion of tumors that crossed the midline or displayed bilateral multifocal involvement was approximately 20% for both genetically defined oligodendrogliomas and astrocytomas. Oligodendrogliomas were most commonly centered in the frontal lobe (66/90, 73%), followed by the parietal (15/90, 17%) and temporal (5/90, 6%) lobes. Noncodeleted tumors were most commonly centered in the frontal lobe (35/58, 60%), followed by the temporal lobe (9/58, 16%), insula (7/58, 12%), and parietal lobe (5/58; 9%). A statistically significant difference in the anatomic distribution of the tumors was noted (P = .02); tumors of the frontal and parietal lobes were more likely to be 1p/19q codeleted oligodendrogliomas, which represented 66/101 (65%) and 15/20 (75%) tumors in these locations, respectively. Insular and temporal tumors were more likely to be noncodeleted.

**Tumor Imaging Features**

Imaging characteristics of the tumors are shown in the On-line Table. Genetically defined oligodendrogliomas were characterized by poorly circumscribed borders (83/90, 92%). Of all tumors in this series with poorly circumscribed borders, most (83/109, 76%) were genetically defined oligodendrogliomas. Oligodendrogliomas generally lacked sharp borders on both T1- and T2-weighted images (87/90, 97% for each) and lacked a smooth contour on T2-weighted images (86/90, 96%). The association between indistinct borders and oligodendroglioma was highly significant for each marker of border sharpness evaluated, compared with astrocytic tumors with some oligodendrogial morphology (P < .0001 for each). The small cohort of internally homogeneous tumors was very unlikely to be codeleted (P = .003 and 0.01 for T1- and T2-weighted images, respectively). Paramagnetic susceptibility, necrosis or cystic change, and contrast enhancement were relatively common in both oligodendrogliomas and astrocytomas, with no significant difference in prevalence. Figure 3 demonstrates prototypical genetically defined oligodendrogliomas and astrocytomas.

In the multivariable analysis (Table 3), tumor location (P values calculated, excluding 2 patients with cerebellar or deep gray location), lack of tumor circumscription (P < .0001), and older age at diagnosis (P = .002) were independently significant predictors of 1p/19q codeleted oligodendroglioma. The odds of oligodendroglioma increased with age (OR, 1.06 for each year; 95% CI, 1.02–1.10) and were strongly predicted by a lack of circumscribed borders (OR, 16.35; 95% CI, 6.08–50.63) relative to tumors with completely or partially circumscribed margins. Although tumor location was not statistically significant overall after adjusting for age and circumscription (P = .06), frontal location tumors were most likely to be codeleted, and the pair-wise comparison between frontal versus temporal was significant (OR, 7.82; 95% CI, 1.66–41.67; P = .01).

**ADC Values**

ADC sequences were available in 65 patients (On-line Table). Tumors with lower mean ADC values were more likely to be 1p/19q codeleted oligodendrogliomas (P = .0005). Receiver operating characteristic analysis identified a mean ADC value of 1.41 mm²/s as the optimal cutoff point, with an area under the curve of 0.76. A mean ADC value of ≤1.41 mm²/s was 73.7% sensitive and 74.1% specific for 1p/19q codeleted oligodendroglioma (Fig 4). In the multivariable analysis, both ADC and tumor circumscription remained statistically significant predictors of oligodendroglioma, while neither patient age nor tumor location remained significant. The odds of oligodendroglioma increased markedly in low-ADC lesions (OR, 5.66 for a half-unit decrease in overall mean ADC; 95% CI, 1.53–27.49; P = .02) and in non-circumscribed tumors (OR, 5.24; 95% CI, 1.27–24.42; P = .02) (Table 4).

**DISCUSSION**

This large retrospective study characterizes findings from commonly obtained MR imaging sequences in genetically defined oligodendrogliomas. These analyses are essential following the WHO 2016 update on CNS tumors, which has led to the reclassification of many infiltrating gliomas. Oligodendrogliomas, now

---

**Table 1: Patient demographics**

|                          | WHO 2016 |                |                |
|--------------------------|----------|----------------|----------------|
|                          | Total    | Oligodendroglia | Astrocytoma    |
|                          | (N = 148)| (lp/19q codeleted) | (non-lp/19q codeleted) |
|                          | (n = 90) | (n = 58)        | (n = 58)        |
| Male sex (No.)           | Male     | 86 (58.1%)      | 49 (54.4%)      |
|                          |Female    | 56 (37.8%)      | 37 (43.0%)      |
| Age, mean (SD), y        | 49.1 ± 13.3| 43.2 ± 13.3    | 49.8 ± 12.5     |

**Table 2: Cross-tabulation of tumor histopathology by WHO 2007 criteria and grade with WHO 2016 criteria for oligodendroglioma (lp/19q codeletion)**

| WHO 2007 classification | Total (N = 148) | Oligodendroglia (lp/19q codeleted) | Astrocytoma (non-lp/19q codeleted) |
|--------------------------|-----------------|-----------------------------------|-----------------------------------|
| Oligodendrogloma         | 60              | 36 (60.0%)                        | 24 (40.0%)                        |
| Oligoastrocytoma         | 86              | 54 (63.0%)                        | 32 (37.0%)                        |
| Tumor grade              |                 |                                   |                                   |
| WHO II                   | 98              | 58 (60.4%)                        | 40 (41.3%)                        |
| WHO III                  | 50              | 32 (64.0%)                        | 18 (36.0%)                        |
| IDH mutation status      |                 |                                   |                                   |
| No.                      | 60              | 39 (65.0%)                        | 21 (35.0%)                        |
| IDH-mutant               | 58              | 39 (67.2%)                        | 19 (32.8%)                        |
| IDH-wild type            | 2               | 0 (0%)                            | 2 (100%)                          |

*χ² test.

**Table 3: Cross-tabulation of tumor histopathology by WHO 2007 criteria and grade with WHO 2016 criteria for oligodendroglioma (lp/19q codeletion)**

| WHO 2007 classification | Total (N = 148) | Oligodendroglia (lp/19q codeleted) | Astrocytoma (non-lp/19q codeleted) |
|--------------------------|-----------------|-----------------------------------|-----------------------------------|
| Oligodendrogloma         | 60              | 36 (60.0%)                        | 24 (40.0%)                        |
| Oligoastrocytoma         | 86              | 54 (63.0%)                        | 32 (37.0%)                        |
| Tumor grade              |                 |                                   |                                   |
| WHO II                   | 98              | 58 (60.4%)                        | 40 (41.3%)                        |
| WHO III                  | 50              | 32 (64.0%)                        | 18 (36.0%)                        |
| IDH mutation status      |                 |                                   |                                   |
| No.                      | 60              | 39 (65.0%)                        | 21 (35.0%)                        |
| IDH-mutant               | 58              | 39 (67.2%)                        | 19 (32.8%)                        |
| IDH-wild type            | 2               | 0 (0%)                            | 2 (100%)                          |
and have higher ADC values. The mean ADC value of the tumor shown in imaging8 had been considered a classic appearance of oligodendroglioma, but only 3%–8% of genetically defined oligodendro- 
gliomas in our series demonstrated well-circumscribed margins, depending on the evaluation criteria used. Other markers previously considered characteristic of oligodendrogliomas, including paramagnetic susceptibility artifacts, cystic change, and bilateral tumor burden,11 were likewise not able to distinguish genetically defined oligodendroglioma from the subset of astrocytomas with oligodendroglial morphology.

Preoperative knowledge of glioma subtype is valuable for patients and clinicians. Standard surgical treatment for glioma is maximum safe resection when possible and biopsy if resection is contraindicated, providing definitive tissue confirmation of tumor type, grade, and genetic markers such as 1p/19q deletion status and IDH mutation. For patients with tumors located where complete resection may result in permanent neurologic deficits, knowledge of whether a tumor is likely to respond well to radiation and/or chemotherapy greatly impacts the risk/benefit analysis of surgery. Because 1p/19q codeletion is both prognostic of survival and predictive of response to radiochemotherapeutic treatment, it significantly informs initial patient counseling and treatment planning.1-3

Efforts to correlate 1p/19q codeletion with imaging features began before the discovery of the IDH mutation and the current WHO revision.12-17 Previous smaller retrospective studies found that 1p/19q codeletion was associated with an indistinct border on T1 and heterogeneity on T1 and T2 images,13 and lack of 1p/19q codeletion was associated with tumor homogeneity and sharp/smooth borders.15 Regarding location, 1p deleted or 1p/19q codeleted oligodendroglial tumors tend to be found in the frontal lobes and not in the temporal lobes.11,12,14,19

In the near future, it may be possible for radiologists to classify most infiltrating gliomas before an operation with a high degree of confidence. In 2016, WHO grade II and III infiltrating gliomas are each broken into 3 categories based on molecular characteristics: astrocytoma IDH-mutant, astrocytoma IDH-wild type, and oligodendroglioma IDH-mutant 1p/19q codeleted tumors. Tumors with mutations in IDH may be identified radiographically by a number of different methods. Mutations in IDH lead to elevated levels of 2-hydroxyglutarate within tumors, which can be identified by MR spectroscopy.20,21 This technique is advancing rapidly and is now in clinical use at some centers.22 Alternatively, methods such as MR perfusion and diffusion tensor imaging have been shown to correlate with IDH-mutation status.23-25 Provided that these techniques, particularly spectroscopy, continue to advance at their present rate, radiographic identification of 1p/19q status could be all that is necessary to categorize WHO grade II and III infiltrating gliomas by imaging.

---

**Table 3: Multivariate model including all standard anatomic imaging elements significantly associated with tumor classification as molecular oligodendroglioma in univariate analysis**

| Location          | Odds Ratio | 95% CI       | P Value | Overall P Value |
|-------------------|------------|--------------|---------|-----------------|
| Frontal           | Reference  |              |         |                 |
| Insular           | 0.36       | 0.07–1.69    | .20     | .06             |
| Parietal          | 0.71       | 0.21–2.65    | .59     |                 |
| Temporal          | 0.13       | 0.02–0.60    | .01     |                 |
| Circumscribed border | Reference |              |         |                 |
| Partial/yes       | 16.35      | 6.08–50.63   | <.0001  |                 |
| No                | 1.06       | 1.02–1.10    | .002    |                 |

*C statistic = 0.84.

---

defined by IDH mutation and 1p/19q codeletion, are likely to demonstrate poorly defined tumor borders, internal heterogeneity, and a lower ADC value compared with astrocytomas with some oligodendroglial morphology. In contrast, noncodeleted infiltrating gliomas demonstrating oligodendroglial morphology, a subset of genetically defined astrocytomas, are more likely to be well-defined and internally homogeneous. Genetically defined oligodendrogliomas have a predilection for the frontal and parietal lobes.

Our results represent a shift from imaging findings previously associated with oligodendrogliomas as defined by the prior histology-based WHO criteria. Circumscribed margins on MR imaging 6 had been considered a classic appearance of oligodendroglioma, but only 3%–8% of genetically defined oligodendrogliomas tend to be located in the temporal or insular lobes, are frequently well circumscribed, and have higher ADC values. The mean ADC value of the tumor shown in F is 192 mm^2/s.
Relatively little has been published on the use of advanced imaging techniques to identify 1p/19q codeletion. While all 1p/19q codeleted oligodendrogliomas are also IDH-mutant, 1p/19q codeletion itself does not have any characteristic findings on MR spectroscopy. Recent publications have evaluated the associations between codeletion and methods such as MR diffusion, MR perfusion, and [18]F-fluoroethyl-L-tyrosine PET.\cite{pet1,pet2,pet3,pet4,pet5,pet6} Our finding of an association between lower ADC values with 1p/19q codeletion has previously been described in small studies.\cite{pet7,pet8} Further investigation will be necessary to define the optimal way of measuring ADC and to determine the physiologic correlate of ADC values in genetically defined oligodendroglioma.\cite{pet9}

While a strength of this current study is its large number of subjects relative to previous publications, it has limitations that should be understood when applying the findings. First, the analysis cohort comprised solely infiltrating gliomas with oligodendrogial features by microscopy. As a result, while the subgroup of 1p/19q codeleted tumors should be representative of most genetically defined oligodendrogliomas, the tumors lacking 1p/19q codeletion represent a subset of astrocytomas with distinct imaging and pathologic features, about which further study is warranted. Furthermore, the rare tumors that are purely astrocytic by morphology but are nonetheless IDH-mutant and 1p/19q codeleted and thus oligodendrogliomas by the 2016 criteria might exhibit different MR imaging characteristics, and further study will be needed to evaluate this question. An additional limitation is that the pretreatment images were performed at a variety of institutions during a number of years. Thus, we were unable to assess the utility of many advanced MR imaging techniques and were only able to preliminarily evaluate the association of ADC values and 1p/19q codeletion. Also, because many of these patients did not have preoperative CT, our evaluation for the previous classic oligodendrogial finding of tumoral calcification was limited.

Because our evaluation of imaging features was through consensus, the interobserver variability with regard to these features remains undetermined. There was substantial and expected overlap in our judgments of tumor circumscription and border sharpness and contour, and the best of these measures to use may be the one with least intra- and interobserver variability, which could be evaluated in a future study. Last, fluorescence in situ hybridization has been and continues to be widely used to assess 1p/19q codeletion, but it may occasionally result in false-positives in tumors with segmental deletions of 1p and 19q rather than the whole arm deletion. In the future, routine use of copy number array testing may allow more precise identification of 1p/19q codeletion and thus oligodendroglioma.

**CONCLUSIONS**

Recent advances in the understanding of glioma pathogenesis, behavior, and treatment underscore the importance of molecular and genetic factors. As tumors become defined by their genetic makeup, as with the WHO 2016 tumor update, it is critical that imaging features that predict genetics are appreciated. Radiologists need to recognize the information already available in routine MR imaging until advanced imaging methods for the confident identification of 1p/19q codeletion are routinely available. On the basis of this study, genetically defined (IDH-mutant and 1p/19q codeleted) oligodendroglioma is much more commonly poorly defined and infiltrative than circumscribed and is almost always heterogeneous in signal intensity. While location within the brain was not as strongly associated with tumor type, genetically defined oligodendrogliomas in this series occurred more frequently in the frontal and parietal lobes than astrocytomas.

**ACKNOWLEDGMENTS**

We wish to sincerely thank Dr Sonia Watson for help in manuscript preparation.

**Table 4: Multivariable models of molecular oligodendroglioma status based on tumor circumscription and ADC value**

| Model | Circumscribed | Partial/yes | No | Overall mean ADC, 0.5 decrease | Odds Ratio | 95% CI | P Value |
|-------|---------------|-------------|----|-------------------------------|------------|--------|---------|
| Model A | Circumscribed | Partial/yes | No | Overall mean ADC, 0.5 decrease | Reference | 5.24 | 1.27–24.42 | .02 |
| Model B | Circumscribed | Partial/yes | No | Mean min ADC, 0.5 decrease | Reference | 5.55 | 1.40–24.99 | .02 |
| Model C | Circumscribed | Partial/yes | No | Mean max ADC, 0.5 decrease | Reference | 3.89 | 1.45–12.58 | .01 |

* Model A indicates mean ADC [C statistic = 0.80]; Model B, minimum ADC [C statistic = 0.74]; and Model C, maximum ADC [C statistic = 0.80].

**FIG 4.** Boxplot demonstrating the distribution of mean ADC values by the WHO 2016 classification as oligodendroglioma or astrocytoma.

(AJNR Am J Neuroradiol 38:678–84 Apr 2017 www.ajnr.org)
REFERENCES

1. Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. *N Engl J Med* 2016;374:1344–55 CrossRef Medline

2. Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendrogial tumors is associated with mutation of IDH. *J Clin Oncol* 2014;32:783–90 CrossRef Medline

3. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol* 2013;31:344–50 CrossRef Medline

4. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. *J Clin Oncol* 2000;18:636–45 Medline

5. Lasman AB. Success at last: a molecular factor that informs treatment. *Carr Oncol Rep* 2013;15:47–55 CrossRef Medline

6. Louis DN, Perry A, Reifenberger G, et al. *The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary*. Acta Neuropathol 2016;131:803–20 CrossRef Medline

7. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. *N Engl J Med* 2015;372:2499–508 CrossRef Medline

8. Osborne AG. *Osborne’s Brain: Imaging, Pathology, and Anatomy*. Salt Lake City: Amirsys; 2013:495

9. Louis DN, Ohgaki H, Wiestler OD, et al. *World Health Organization Classification of Tumours of the Central Nervous System*. Lyon: International Agency for Research on Cancer; 2007

10. Jenkins RB, Xiao Y, Sicotte H, et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendrogial tumors and astrocytomas with IDH1 or IDH2 mutation. *Nat Genet* 2012;44:1122–25 CrossRef Medline

11. Zlatescu MC, Tehran-Yazi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendrogial neoplasms. *Cancer Res* 2001;61:6713–15 Medline

12. Laiq-Lenaday F, Martin-Duverneuil N, Lejeune J, et al. Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. *Neurology* 2004;63:2360–62 CrossRef Medline

13. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendroglia. *Clin Cancer Res* 2010;16:4303–06 CrossRef Medline

14. Walker C, du Plessis DG, Fildes D, et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. *Clin Cancer Res* 2004;10:7182–91 CrossRef Medline

15. Jenkins MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumors: correlation with MRI features. *Brain* 2006;129:1884–91 CrossRef Medline

16. Jenkins MD, Smith TS, Brodbelt AR, et al. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. *J Magn Reson Imaging* 2007;26:1405–12 CrossRef Medline

17. Brown R, Zlatescu M, Siiben A, et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. *Clin Cancer Res* 2008;14:2357–62 CrossRef Medline

18. Kim JW, Park CK, Park SH, et al. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendrogial tumours. *J Neurol Neurosurg Psychiatry* 2011;82:224–27 CrossRef Medline

19. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. *Am J Pathol* 2002;161:313–19 CrossRef Medline

20. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxylglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. *Sci Transl Med* 2012;4:116ra4 CrossRef Medline

21. Andronesi OC, Rapalino O, Gerstner E, et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxylglutarate. *J Clin Invest* 2013;123:3659–63 CrossRef Medline

22. de la Fuente MI, Young RJ, Rubel J, et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. *Neuro Oncol* 2016;18:283–90 CrossRef Medline

23. Kickingeder P, Sahn F, Radbruch A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. *Sci Rep* 2015;5:16238 CrossRef Medline

24. Qi S, Yu L, Li H, et al. Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. *OncoLett* 2014;7:1895–902 Medline

25. Xiong J, Tan W, Wen J, et al. Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendrogial tumours. *Eur Radiol* 2016;26:1705–15 CrossRef Medline

26. Jansen NL, Schwartz C, Graute V, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic (18)F-FET-PET imaging in intracranial WHO grade II and III gliomas. *Neuro Oncol* 2012;14:1473–80 CrossRef Medline

27. Chawla S, Krejza J, Vossough A, et al. Differentiation between oligodendroglia genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. *AJNR Am J Neuroradiol* 2013;34:1542–49 CrossRef Medline

28. Fellah S, Caudal D, De Paula AM, et al. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendrogial tumor grade and 1p/19q codelletion in the pretherapeutic diagnosis? *AJNR Am J Neuroradiol* 2013;34:1326–33 CrossRef Medline

29. Saito T, Muragaki Y, Maruyama T, et al. Calculation on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. *Brain Tumor Pathol* 2016;33:175–82 CrossRef Medline

30. Khayal IS, Vandenberg SR, Smith KJ, et al. MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. *Neuro Oncol* 2011;13:1192–201 CrossRef Medline